Purpose of Review: To systematically review the evidence on prostate cancer (PCa) in transgender women (TGW). Recent Findings: A total of 25 studies were included. Fourteen articles were case reports or case series describing 21 TGW with PCa; 11 papers focused primarily on assessing the incidence or screening of PCa in TGW. The median (range) age of patients with PCa was 63 (45-78) years. Median (range) PSA at diagnosis was 7.5 (0.4-1710) ng/mL. Prostate biopsy detected ISUP 3-5 in 10 (67%) cases. T3-4 stages were described in 7 (64%) patients. Three (14.3%) cases of nodal involvement and 2 (9.5%) of metastases were reported at diagnosis. First-line therapy included radical prostatectomy or radiotherapy +/- androgen deprivation therapy in 14 (74 %) subjects. Median (range) follow-up was 24 (2-120) months. A good response to first-line therapy was recorded in 8 (47.1%) cases. Median (range) incidence of PCa in TGW was 44.1 (4.34-140) cases per 100,000 person-years. PCa was significantly less frequent in TGW than in cisgender males (HR 0.4, 95% CI 0.2-0.9). Risk of death after PCa diagnosis was significantly higher in TGW compared to cisgender males (HR 1.91, 95% CI 1.06-3.45). TGW had lower lifetime PSA rates (48% vs. 64.6%, p = 0.048) than cisgender males.SummaryFew cases of PCa in TGW are currently reported. PCa seems significantly less frequent in TGW than in cisgender males; however, some data suggest a possible higher mortality in this cohort. TGW appear to have less access to PSA testing than cisgender men.

Prostate cancer in transgender women: epidemiology, clinical characteristics, and management challenges / Manfredi, Celeste; Ditonno, Francesco; Franco, Antonio; Bologna, Eugenio; Licari, Leslie Claire; Arcaniolo, Davide; Tubaro, Andrea; De Nunzio, Cosimo; Antonelli, Alessandro; De Sio, Marco; Cherullo, Edward E; Autorino, Riccardo. - In: CURRENT ONCOLOGY REPORTS. - ISSN 1523-3790. - 25:12(2023), pp. 1431-1443. [10.1007/s11912-023-01470-w]

Prostate cancer in transgender women: epidemiology, clinical characteristics, and management challenges

Ditonno, Francesco;Franco, Antonio;Bologna, Eugenio;Licari, Leslie Claire;Tubaro, Andrea;De Nunzio, Cosimo;Antonelli, Alessandro;
2023

Abstract

Purpose of Review: To systematically review the evidence on prostate cancer (PCa) in transgender women (TGW). Recent Findings: A total of 25 studies were included. Fourteen articles were case reports or case series describing 21 TGW with PCa; 11 papers focused primarily on assessing the incidence or screening of PCa in TGW. The median (range) age of patients with PCa was 63 (45-78) years. Median (range) PSA at diagnosis was 7.5 (0.4-1710) ng/mL. Prostate biopsy detected ISUP 3-5 in 10 (67%) cases. T3-4 stages were described in 7 (64%) patients. Three (14.3%) cases of nodal involvement and 2 (9.5%) of metastases were reported at diagnosis. First-line therapy included radical prostatectomy or radiotherapy +/- androgen deprivation therapy in 14 (74 %) subjects. Median (range) follow-up was 24 (2-120) months. A good response to first-line therapy was recorded in 8 (47.1%) cases. Median (range) incidence of PCa in TGW was 44.1 (4.34-140) cases per 100,000 person-years. PCa was significantly less frequent in TGW than in cisgender males (HR 0.4, 95% CI 0.2-0.9). Risk of death after PCa diagnosis was significantly higher in TGW compared to cisgender males (HR 1.91, 95% CI 1.06-3.45). TGW had lower lifetime PSA rates (48% vs. 64.6%, p = 0.048) than cisgender males.SummaryFew cases of PCa in TGW are currently reported. PCa seems significantly less frequent in TGW than in cisgender males; however, some data suggest a possible higher mortality in this cohort. TGW appear to have less access to PSA testing than cisgender men.
2023
prostate cancer; transgender; transsexual; transwoman
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Prostate cancer in transgender women: epidemiology, clinical characteristics, and management challenges / Manfredi, Celeste; Ditonno, Francesco; Franco, Antonio; Bologna, Eugenio; Licari, Leslie Claire; Arcaniolo, Davide; Tubaro, Andrea; De Nunzio, Cosimo; Antonelli, Alessandro; De Sio, Marco; Cherullo, Edward E; Autorino, Riccardo. - In: CURRENT ONCOLOGY REPORTS. - ISSN 1523-3790. - 25:12(2023), pp. 1431-1443. [10.1007/s11912-023-01470-w]
File allegati a questo prodotto
File Dimensione Formato  
Manfredi_Prostate-cancer_2024.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 969.14 kB
Formato Adobe PDF
969.14 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1705855
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact